

New Indications

Onglyza (**saxagliptin**) is now indicated as triple oral combination therapy in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin plus a sulfonylurea when the two agents, with diet and exercise, do not provide adequate glycaemic control.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.